A SARS-CoV-2 recombinant spike protein vaccine (S-268019-b) for COVID-19 prevention during the Omicron-dominant period: A phase 3, randomised, placebo-controlled clinical trial
Article in Vaccine (May 2024)
The most recent citing publications are shown below. View all 3 publications that cite this research output on Dimensions.
Article in Vaccine (May 2024)
Article in Future Virology (June 2023)
Article in PLOS ONE (May 2023)